Literature DB >> 8564522

The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A.

D A Hartman1, S J Ochalski, R P Carlson.   

Abstract

IL-1 beta, IL-8, IL-6 and TNF alpha, derived from infiltrating leukocytes, are important mediators of inflammation in arthritic and allergic diseases. Heparinized human whole blood was evaluated as a model to study the effects of various classes of antiinflammatory drugs on cytokine release/biosynthesis from leukocytes. Whole blood was stimulated with zymosan A (1.5 mg/ml) or LPS (5 micrograms/ml) for 4 h to induce cytokine release. Dexamethasone was the most potent inhibitor of TNF alpha, IL-1 beta, IL-6 and IL-8 release from LPS stimulated blood leukocytes (IC50s of 0.19, 0.11 microM, 0.16 and 0.07 respectively). In LPS stimulated blood, SKF-86002, a 5-lipoxygenase/cytooxygenasae inhibitor, and rolipram, a PDE IV inhibitor, also inhibited the release of TNF alpha (IC50s of 33 and 11 microM, respectively), IL-1 beta (IC50s of 11 and 30 microM, respectively), IL-6 (IC50s of 56 and > 30, respectively) and IL-8 (IC50s of 6.7 and 15, respectively), whereas isoproterenol (1 microM) inhibited significantly only TNF alpha release. Nonsteroidal antiinflammatory drugs, 5-lipoxygenase inhibitors and immuno-suppressive drugs were inactive at 30 microM against LPS and zymosan A stimulation of cytokine release. Using zymosan A as the stimulus, only SKF-86002 (30 microM) showed significant inhibition of IL-1 beta (-59%). This 4 h human blood assay has the potential to identify novel inhibitors and sites of actions (e.g. transcription, post-transcriptional and secretion) of new antiinflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564522     DOI: 10.1007/bf02032567

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  36 in total

1.  Tumor necrosis factor-alpha gene expression in human whole blood.

Authors:  R M Strieter; D G Remick; J M Ham; L M Colletti; J P Lynch; S L Kunkel
Journal:  J Leukoc Biol       Date:  1990-04       Impact factor: 4.962

Review 2.  The IL-1 beta converting enzyme as a therapeutic target.

Authors:  D K Miller; J R Calaycay; K T Chapman; A D Howard; M J Kostura; S M Molineaux; N A Thornberry
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

Review 3.  Role of cytokines in experimental arthritis.

Authors:  F M Brennan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 4.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

5.  Platelet-activating factor and leukotriene biosynthesis in whole blood. A model for the study of transcellular arachidonate metabolism.

Authors:  A Fradin; J A Zirrolli; J Maclouf; L Vausbinder; P M Henson; R C Murphy
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

6.  The effects of anti-inflammatory and antiallergic drugs on the release of IL-1 beta and TNF-alpha in the human whole blood assay.

Authors:  D A Hartman; S J Ochalski; R P Carlson
Journal:  Agents Actions       Date:  1993

7.  Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood.

Authors:  L E DeForge; D G Remick
Journal:  Biochem Biophys Res Commun       Date:  1991-01-15       Impact factor: 3.575

8.  The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes.

Authors:  D M Chang; P Baptiste; P H Schur
Journal:  J Rheumatol       Date:  1990-09       Impact factor: 4.666

9.  Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA.

Authors:  S W Lee; A P Tsou; H Chan; J Thomas; K Petrie; E M Eugui; A C Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

10.  Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors.

Authors:  K L Molnar-Kimber; L Yonno; R J Heaslip; B M Weichman
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more
  4 in total

1.  Inflammation-Responsive Drug-Conjugated Dextran Nanoparticles Enhance Anti-Inflammatory Drug Efficacy.

Authors:  Sangeun Lee; Alexandra Stubelius; Naomi Hamelmann; Vincent Tran; Adah Almutairi
Journal:  ACS Appl Mater Interfaces       Date:  2018-11-13       Impact factor: 9.229

2.  The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.

Authors:  C Brideau; C Van Staden; A Styhler; I W Rodger; C C Chan
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.

Authors:  S Sakuma; Y Kato; F Nishigaki; T Sasakawa; K Magari; S Miyata; Y Ohkubo; T Goto
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.

Authors:  Maria Dona; Gabrielle Fredman; Jan M Schwab; Nan Chiang; Makoto Arita; Ahmad Goodarzi; Guiying Cheng; Ulrich H von Andrian; Charles N Serhan
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.